PerkinElmer to Acquire High-Throughput Screening Shop Evotec Tech for $30.5M | GenomeWeb
NEW YORK (GenomeWeb News) — PerkinElmer plans to acquire high-throughput screening Evotec Technologies for €23 million ($30.5 million) in cash, German parent company Evotec said late yesterday.
 
Evotec makes and sells tools for high-throughput and high-content cell and biochemical screening. PerkinElmer CEO Gregory Summe said in a statement that the acquisition will “help our customers speed target validations and lead optimization along the drug discovery value chain.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.